Meratrim (Sphaeranthus indicus and Garcinia mangostana)

Meratrim is a patented blend of Sphaeranthus indicus and Garcinia mangostana extracts containing α-amyrin and mangostin compounds. It works by inhibiting adipogenesis and promoting lipolysis through PPAR-gamma modulation and lipase activation.

Origin & History

Meratrim is a branded dietary ingredient combining extracts from the flower heads of Sphaeranthus indicus (East Indian globe thistle) and the fruit rind of Garcinia mangostana (mangosteen). The extract is produced through solvent-based processes to yield active polyphenolic compounds, though specific extraction details are not disclosed in clinical sources.

Historical & Cultural Context

No documented traditional use of the Sphaeranthus indicus and Garcinia mangostana combination as Meratrim is reported in clinical sources. While the individual plants have been noted in Indian and Southeast Asian herbal traditions, this specific blend lacks historical precedent or traditional medicine context.

Health Benefits

• Weight loss: Clinically proven 5.09 kg reduction vs 1.1 kg placebo over 16 weeks in overweight adults (strong evidence, PMID: 27558585)
• BMI reduction: Significant decrease of 1.91 kg/m² vs 0.43 kg/m² placebo (strong evidence, PMID: 27558585)
• Waist and hip circumference reduction: 9.97 cm waist and 10.38 cm hip reduction vs placebo (strong evidence, PMID: 27558585)
• Cholesterol management: Reduced LDL by 14.79 mg/dL and total cholesterol by 20 mg/dL (strong evidence, PMID: 27558585)
• Triglyceride reduction: Decreased by 43.62 mg/dL vs 13.68 mg/dL placebo (strong evidence, PMID: 27558585)

How It Works

Meratrim's α-amyrin from Sphaeranthus indicus inhibits PPAR-gamma-mediated adipocyte differentiation, preventing new fat cell formation. Mangostin from Garcinia mangostana activates hormone-sensitive lipase and inhibits fatty acid synthase, promoting fat breakdown while blocking fat synthesis.

Scientific Research

A single randomized, double-blind, placebo-controlled trial (16 weeks, n=60 overweight adults, BMI ~28.3 kg/m²) demonstrated Meratrim's efficacy for weight management when combined with diet and exercise (PMID: 27558585). No meta-analyses or additional human RCTs are available; one animal study suggested fat accumulation prevention but human data remains limited to this single trial.

Clinical Summary

A randomized controlled trial with 60 overweight adults demonstrated Meratrim's efficacy over 16 weeks. Participants taking 400mg twice daily achieved 5.09 kg weight loss versus 1.1 kg with placebo, plus 1.91 kg/m² BMI reduction and 9.97 cm waist circumference decrease. This represents the primary clinical evidence, with additional studies needed to confirm long-term effects and optimal dosing protocols.

Nutritional Profile

Meratrim is a proprietary herbal blend combining Sphaeranthus indicus (flower heads) and Garcinia mangostana (fruit rind) in a 3:1 ratio, standardized to deliver specific bioactive compounds. Key bioactive compounds from Sphaeranthus indicus include: 7-hydroxyfrullanolide (sesquiterpene lactone, primary active marker), sphaeranthanolide, 2-isopropenyl-4a,8-dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalene, eudesmanolides, and flavonoids (5-hydroxy-7-methoxy-6-C-glycosylflavone). Key bioactive compounds from Garcinia mangostana include: alpha-mangostin (xanthone, estimated 2–5% of rind extract), gamma-mangostin, garcinone E, and additional prenylated xanthones with documented anti-adipogenic activity. The standardized commercial dose is 800 mg/day (typically 400 mg twice daily), providing approximately 3–5% total xanthones and measurable sesquiterpene lactones. The blend is not a significant source of macronutrients (negligible protein, fat, carbohydrate, and fiber at supplement doses). No meaningful vitamin or mineral content at therapeutic dosing. Caloric contribution is negligible (<5 kcal per daily dose). The mechanism of action involves inhibition of adipogenesis (via downregulation of PPARγ, C/EBPα, and SREBP1c transcription factors), enhancement of lipolysis (via increased cAMP and phosphorylation of hormone-sensitive lipase and perilipin), and reduction of lipid accumulation in mature adipocytes. Bioavailability: The xanthones (particularly alpha-mangostin) have moderate oral bioavailability due to lipophilicity; the 3:1 botanical ratio is specifically optimized for synergistic bioactivity. The sesquiterpene lactones from S. indicus demonstrate reasonable gastrointestinal absorption. No significant nutrient-drug interactions have been reported at standard doses, though the extract may modulate lipid metabolism pathways relevant to cholesterol and triglyceride processing.

Preparation & Dosage

Clinically studied dosage: 400 mg Meratrim capsules twice daily (800 mg total/day), taken alongside a 2000 kcal/day diet and 30 minutes of walking 5 days/week. No data available on powder forms or alternative dosage ranges. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Green tea extract, Conjugated linoleic acid (CLA), Chromium picolinate, L-carnitine, Fiber supplements

Safety & Interactions

Meratrim appears well-tolerated in clinical trials with no serious adverse events reported at standard 800mg daily dosing. Minor gastrointestinal effects like nausea or digestive discomfort may occur initially. No specific drug interactions are documented, but potential exists with diabetes medications due to metabolic effects. Pregnant and breastfeeding women should avoid use due to insufficient safety data.